Trandolapril: a clinical profile.
Trandolapril is a new angiotensin converting enzyme (ACE) inhibitor that effectively lowers blood pressure in doses up to 2 mg. Only a small additional effect is seen with higher doses. The drug is transformed in vivo to the active metabolite trandolaprilat. When renal function is severely impaired a dose reduction may be necessary because the clearance of trandolaprilat is significantly correlated to creatinine clearance. Trandolapril has a sustained action that is reflected in long-lasting inhibition of ACE, even after discontinuation of treatment. Blood pressure is controlled by the drug in about 60% of patients with a side effect profile that is comparable to that of the other ACE inhibitors. Trandolapril can be given safely over a prolonged period of time.
de Leeuw
P W
PW
Department of Medicine, University Hospital Maastricht, The Netherlands.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007211:Indoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007211:Indoles; C052035:trandolapril